<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Advantages and disadvantages of oral anticoagulants (warfarin versus direct oral anticoagulants*)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Advantages and disadvantages of oral anticoagulants (warfarin versus direct oral anticoagulants*)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Advantages and disadvantages of oral anticoagulants (warfarin versus direct oral anticoagulants*)</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup> <colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Warfarin</td> <td class="subtitle1">Direct oral anticoagulants*</td> </tr> <tr> <td><strong>Dosing</strong></td> <td>Once-daily dosing may be more convenient.</td> <td>May require more frequent dosing.</td> </tr> <tr> <td><strong>Dietary restrictions</strong></td> <td>Need to ensure relatively constant level of vitamin K intake.</td> <td>None. Rivaroxaban doses ≥15 mg should be taken with food.</td> </tr> <tr> <td><strong>Monitoring therapy</strong></td> <td>PT/INR monitoring is required, which entails regular visits to a facility for most patients (point-of-care devices may be an option for some).</td> <td>Not required; however, noncompliance will not be as readily apparent. It may be reasonable to obtain drug levels in some settings (eg, altered gastrointestinal anatomy) to ensure that the drug is being absorbed.</td> </tr> <tr> <td><strong>Drug interactions</strong></td> <td>Many.</td> <td>Rivaroxaban and apixaban interact with CYP-3A4 and P-glycoprotein inhibitors or inducers; edoxaban and dabigatran interact with P-glycoprotein inducers or inhibitors.</td> </tr> <tr> <td><strong>Time in therapeutic range</strong></td> <td>Approximately 65% based on clinical trials.</td> <td>Expected to be superior to warfarin, although therapeutic ranges have not been established.</td> </tr> <tr> <td><strong>Reversal agent(s)</strong></td> <td>Several available (eg, vitamin K, FFP, PCC).</td> <td>For dabigatran: idarucizumab; for direct factor Xa inhibitors: andexanet alfa. Activated charcoal may be used to remove unabsorbed drug if the last ingestion was recent. Hemodialysis may be used to remove dabigatran from the circulation.</td> </tr> <tr> <td><strong>Monitoring drug activity after reversal</strong></td> <td>PT/INR can be used.</td> <td>TT can be used for dabigatran; anti-factor Xa activity can be used for apixaban.</td> </tr> <tr> <td><strong>Effect of comorbid conditions</strong></td> <td>May increase fracture risk, especially in individuals with underlying osteoporosis.</td> <td>Renal function affects pharmacokinetics; dosing unclear in those with obesity.</td> </tr> </tbody></table></div><div class="graphic_lgnd">The factors listed may be considered in making decisions regarding choice of oral anticoagulant, but these must be considered together with clinical information regarding efficacy and toxicity in specific medical conditions. Refer to the UpToDate topic reviews on specific medical conditions for clinical data and expert opinion regarding the choice of oral anticoagulants. Refer to UpToDate topics on warfarin and direct thrombin and factor Xa inhibitors for further details on administration of these agents and management of bleeding associated with their use. Refer to UpToDate tables on drug interactions and the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> database for descriptions of drug interactions with agents described herein.</div><div class="graphic_footnotes"><p>VTE: venous thromboembolism; PT: prothrombin time; INR: international normalized ratio; FFP: fresh frozen plasma; PCC: prothrombin complex concentrates; rFVIIa: recombinant activated factor VII; TT: thrombin time.</p>
* Direct oral anticoagulants include direct thrombin inhibitors (eg, dabigatran) and direct factor Xa inhibitors (eg, apixaban, edoxaban, rivaroxaban).</div><div id="graphicVersion">Graphic 91199 Version 19.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
